Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | Phase 1 | terminated | Oct 20, 2008 | Kyowa Kirin Co., Ltd. | lack of efficacy in Multiple myeloma | Efficacy / futility |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and… | Phase 1 / Phase 2 | terminated | Jan 21, 2016 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT…(AHCT) | Early Phase 1 | withdrawn | Aug 19, 2021 | Koen van Besien | The original principal Investigator left the institution. | Investigator |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Phase 1 / Phase 2 | terminated | Sep 20, 2017 | Poseida Therapeutics, Inc. | Phase I portion of the study was completed. The phase II portion of the study was terminated early… | Other (stated, no rule matched) |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | Phase 1 | terminated | Sep 10, 2019 | Washington University School of Medicine | Decision made to not move forward with Phase II portion of trial | Other (stated, no rule matched) |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | After CAR-T treatment, the benefit is not significant, and it is difficult to enroll. | Enrollment / accrual |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | Phase 2 | terminated | Mar 7, 2016 | University of Nebraska | Study terminated prematurely due to poor recruitment. | Enrollment / accrual |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40… | Phase 1 / Phase 2 | terminated | Dec 7, 2023 | GlaxoSmithKline | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With… | Phase 1 | terminated | Dec 7, 2022 | Anaveon AG | The study was ended due to a lack of recruitment | Enrollment / accrual |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe… | Phase 1 | terminated | Jun 3, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell… | Phase 1 | withdrawn | Jul 10, 2020 | Fred Hutchinson Cancer Center | NIH terminated funding. Study was closed before any participants were enrolled. | Enrollment / accrual |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients…(OCEAN) | Phase 3 | terminated | May 12, 2017 | Oncopeptides AB | Sponsor assessed all endpoints and collected Overall Survival data for another two years following… | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer… | Phase 2 | terminated | Jul 10, 2020 | OHSU Knight Cancer Institute | Insufficient accrual rate | Enrollment / accrual |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | suspended | Aug 10, 2020 | NexImmune Inc. | Lack of accrual | Enrollment / accrual |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat… | Phase 1 | terminated | Apr 18, 2018 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT03657251 | MMRF CureCloud Research Initiative | — | terminated | Sep 5, 2018 | Multiple Myeloma Research Foundation | The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared… | Other (stated, no rule matched) |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201… | Phase 1 | withdrawn | Aug 8, 2023 | The First Affiliated Hospital of Soochow University | Molecular development strategy adjustment | Sponsor / business decision |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab… | Phase 3 | terminated | Sep 16, 2020 | GlaxoSmithKline | The study has been terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | Phase 1 / Phase 2 | withdrawn | Apr 29, 2021 | University of Virginia | Slow accrual due to a crowded field of effective drugs by the time the study opened | Enrollment / accrual |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other… | Phase 1 / Phase 2 | withdrawn | Dec 12, 2022 | LaNova Medicines Limited | According to sponsor strategy | Sponsor / business decision |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal…(PENTI-MIDAS) | Phase 2 | withdrawn | Apr 11, 2022 | Nantes University Hospital | MIDAS inclusions terminated before first inclusion in PENTI-MIDAS | Other (stated, no rule matched) |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | Phase 2 | terminated | Jul 11, 2014 | Oncotherapeutics | Lack of enrollment | Enrollment / accrual |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2… | Phase 2 | terminated | Nov 19, 2014 | Oncotherapeutics | Early termination due to the difficulties to enroll subjects. | Enrollment / accrual |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase 2 | terminated | Nov 7, 2018 | Oncotherapeutics | Insufficient enrollment | Enrollment / accrual |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone…(ClaSPd) | Phase 2 | terminated | Apr 13, 2021 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With… | Phase 1 | terminated | Oct 24, 2017 | Kite, A Gilead Company | The study was terminated due to lack of efficacy | Efficacy / futility |
| NCT04805203 | Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma(Covimmunomm) | N/A | terminated | Mar 18, 2021 | Intergroupe Francophone du Myelome | Recruitment delay due to difficulties to involve patient at Covid diagnosis in hematology… | COVID-19 / pandemic |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for… | Phase 1 / Phase 2 | terminated | Aug 9, 2010 | Sherif Farag, MB, BS | Lack of accrual | Enrollment / accrual |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed… | Phase 2 | terminated | Dec 19, 2019 | Srinivas Devarakonda | Poor accrual | Enrollment / accrual |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating… | Phase 1 / Phase 2 | withdrawn | Oct 10, 2018 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04142619 | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With… | Phase 1 | terminated | Oct 29, 2019 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. | Safety / toxicity |
| NCT04171843 | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With… | Phase 1 | terminated | Nov 21, 2019 | Precision BioSciences, Inc. | Study was terminated due to lack of sufficient therapeutic effect | Other (stated, no rule matched) |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Phase 1 | terminated | Jan 26, 2023 | Virtuoso BINco, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory… | Phase 1 / Phase 2 | terminated | Jun 28, 2017 | University of Nebraska | Phase I response to treatment was not as expected and the myeloma field in treatment has changed… | Other (stated, no rule matched) |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide,… | Phase 2 | withdrawn | Feb 6, 2020 | Canadian Myeloma Research Group | Study terminated due to changing treatment landscape | Other (stated, no rule matched) |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk… | Phase 2 | terminated | Sep 20, 2016 | Hackensack Meridian Health | FDA Hold Due to Updated Risks | Other (stated, no rule matched) |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | Phase 2 | terminated | Oct 8, 2019 | Andrew Yee, MD | Study closure initiated by industry funding sponsor for commercial reasons. | Funding |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | Early Phase 1 | withdrawn | Jul 19, 2018 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | withdrawn | Jun 26, 2023 | ModernaTX, Inc. | The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons. | Sponsor / business decision |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Phase 1 | terminated | Dec 30, 2019 | AstraZeneca | Strategic change to clinical development plan | Sponsor / business decision |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | Phase 2 | terminated | Jun 9, 2016 | University of Pennsylvania | Study was terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With… | Phase 2 | terminated | Dec 20, 2018 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in…(LIGHTHOUSE) | Phase 3 | terminated | Dec 2, 2020 | Oncopeptides AB | The sponsor decided to terminate the study due to financial issues following an FDA request for a… | Funding |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | Phase 3 | terminated | Aug 6, 2015 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT02063113 | Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.(MYELOME-PA) | N/A | terminated | Feb 14, 2014 | Nantes University Hospital | inclusion difficulty | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 25, 2024source: clinicaltrials